Long-term outcome of sunitinib in metastatic renal cell carcinoma: Single center experience.

e15606 Background: The multi-target tyrosine-kinase inhibitor sunitinib has been widely used in first or subsequent lines of treatment for metastatic renal cell carcinoma (mRCC). Since results of r...